ScholarX: NAM, DO HYUN

Detailed Information

NAM, DO HYUN (남도현)

Medicine (Medicine)

Research Area: 암줄기세포, 신경줄기세포, 중개연구

Tel 02-3410-3497
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Glioblastoma:31||glioblastoma:26||Gamma knife radiosurgery:13||Stereotactic radiosurgery:11||Temozolomide:11||Radiosurgery:8||Radiotherapy:8||Brain metastases:7||radiosurgery:6||glioma:6||Recurrence:6||Glioblastoma multiforme:6||Vestibular schwannoma:5||EGFR:5||radiotherapy:5||Survival:5||Endoscopic endonasal surgery:4||Endoscopic endonasal approach:4||temozolomide:4||Cancer:4||cMet:4||Cerebrospinal fluid leak:4||Magnetic resonance imaging:4||Oncology:4||Brain metastasis:4||Gamma knife:4||recurrence:4||Craniopharyngioma:4||MGMT:3||highthroughput screening:3||Pituitary adenoma:3||IDH1:3||radiogenomics:3||brain metastasis:3||Tumor microenvironment:3||survival:3||brain tumor:3||Irinotecan:3||cancer stem cell:3||glioblastoma multiforme:3||oncology:3||Endoscopic surgery:3||Cavernous sinus:3||Prognosis:3||endoscopic transorbital approach:3||3D cell culture:3||gliomatosis cerebri:3||Colorectal cancer:3||Highgrade glioma:3||Meningioma:3||pharmacokinetics:3||Gamma Knife radiosurgery:3||colorectal cancer:3||Metastatic brain tumor:3||Glioma stem cells:3||surgical technique:2||Machine learning:2||TTAC0001:2||cancer genomics:2||Asymptomatic meningioma:2||Radiation therapy:2||Carboxyl esterase (CE):2||carcinoma:2||cell encapsulation in alginate:2||meningioma:2||Endoscopic transsphenoidal surgery:2||Therapeutic target:2||mesenchymal subtype:2||metastasis:2||Optic coherence tomography:2||methotrexate:2||cerebrospinal fluid leak:2||tumor microenvironment:2||TopBP1:2||Toxicity:2||Metastasis:2||combination therapy:2||CNS lymphoma:2||myelinassociated infiltration:2||Brain tumors:2||xenograft:2||Chemoradiation:2||neoplasm metastasis:2||Microsurgery:2||Gliomatosis cerebri:2||nogo receptor:2||Chemotherapy:2||Tumor heterogeneity:2||Anaplastic glioma:2||Tumor progression:2||Cell Biology:2||Risk factor:2||Drug response:2||Patientderived xenograft:2||Hemangioblastoma:2||endoscopic endonasal approach:2||Fluorescence microscope images:2||Phage display:2||CD133:2||Fractionated stereotactic radiosurgery:2||pituitary adenoma:2||Visual outcome:2||Pituitary gland:2||fully human antibody:2||Fully human antibody:2||gamma knife:2||gamma knife radiosurgery:2||Pituitary surgery:2||Elderly:2||Brain tumor:2||Leptomeningeal seeding:2||Precision medicine:2||Skull base:2||Cancer stem cell:2||Hydrocephalus:2||radiomics:2||Nemolike kinase:2||DNA damage response:2||angiogenesis:2||Skull base surgery:2||Gamma Knife:2||Prognostic factor:2||Lung cancer:2||Neural stem cells:2||Lymphoma:2||Proteomics:2||MET:2||assay miniaturization:2||Endoscopic:2||Nonsmall cell lung cancer:2||RNA interference screen:2||brain:2||hypofractionation:2||TP53:2||surgery:2||Facial palsy:1||Fluorescence in situ hybridization:1||Fractionated Gamma Knife radiosurgery:1||Fractionated radiosurgery:1||Fractionated radiotherapy:1||Fractionation schedule:1||Functional validation:1||GBM stem cells:1||GD2:1||Ga:1||Gamma Knife Radiosurgery:1||Gamma Knife surgery:1||Gamma knife surgery:1||Gastric cancer:1||Gefitinib:1||Gene expression profiling:1||Genome:1||Genomic profile:1||Giant solid hemangioblastoma:1||Glioblastoma multiforme (GBM):1||Glioblastoma stem cells:1||Glioma:1||Glioma with 1p/19q codeletion:1||Gynecologic malignancy:1||H:1||HER2:1||HER2overexpressing breast cancer:1||HGF:1||Hearing:1||Hearing preservation:1||Hemangiopericytoma:1||High Throughput Screening:1||Highcontent screening:1||Hippocampus:1||HnRNPC:1||Hormonal recovery:1||Hormone replacement therapy:1||Human astrocytes:1||Human brain endothelial cells:1||Human neural stem cell:1||Hydroxyapatite cemen:1||Hyperprolactinemia:1||Hypopituitarism:1||Hypoxia:1||ID2:1||ID3:1||IDH2:1||IRCR201:1||Id4:1||Image quantification:1||Image stitching:1||Imaging agents:1||Immune response:1||Immune therapy:1||Immunotherapy:1||In vitro BBB model:1||In vitro drug screening:1||In vitro expansion:1||Invitro BBB Model:1||Injectable hydroxyapatite:1||Ink4a/Arf(/) astrocyte:1||Intensitymodulated radiation therapy:1||Interfraction interval:1||Interfractional volume change:1||Intracranial:1||Intracranial metastases:1||Intracranial pressure:1||Intrathecal
chemotherapy:1||Intraventricular tumor:1||Invasi:1||Irradiation:1||Isocitrate dehydrogenase:1||Jugular foramen:1||Kras:1||KRAS mutation:1||Korean GBM patients:1||Large vestibular schwannoma:1||Learning curve:1||Leptomeningeal carcino:1||Leptomeningeal metastases:1||Leptomeningeal spread:1||Longitudinal molecular profiling:1||Lowlying chiasm:1||Lumbar drainage:1||Lymphopenia:1||MET amplification:1||MET dysregulation:1||MET tyrosinekinase inhibitor:1||MLN4924:1||MRI:1||MRI schedule:1||Malignant glioma:1||Malignant gliomas · Neuronal marker · Methylation status of O6methylguanineDNA methyltransferase · Expression of isocitrate dehydrogenase 1 · 1p and 19q.:1||Manganese:1||Mass Spectrometry:1||Maximal safe resection:1||Meckel’s cave:1||Mesenchymal:1||Metformin:1||Methylation:1||MicroRNA1:1||Microarray analysis:1||Microsurgical resection:1||Microvasculature:1||Middle cranial fossa:1||Middle fossa tumors:1||Midline anterior sku:1||Mitochondrial permeability transition pore (mPTP):1||Mitogenactivated protein kinase kinase kinase 8:1||Mixed gangliocytoma pituitary adenoma:1||Molecular change:1||Molecular diagnostics:1||Multimodality:1||Multicentric:1||Multilayer technique:1||Multiple:1||Multipotent neural cells:1||Muscleinvasive urothelial bladder cancer:1||Mutant SOD1 transgenic mouse:1||Mutation:1||NAB2STAT6:1||NEDD8:1||Nanoparticles:1||Nasoseptal flap:1||Natural history:1||Natural killer cell:1||Neddylation:1||Neoadjuvant chemotherapy:1||Neoplasm metastasis:1||Neural stem cell:1||Neurofibromatosis type 2:1||Neurological diseases:1||Neuronavigation:1||Neutralization:1||Nonfunctioning pituitary adenomas:1||Nonsmall cell lung cancer · EGFR · Kras · ALK · Gamma knife radiosurgery:1||Nonsmallcell lung:1||Nonsmallcell lung cancer:1||Nonfunctioning:1||Nonfunctioning pituitary adenoma:1||O6methylguanineDNA methyltransferase:1||O6methylguaninDNA m:1||Olfaction disorders:1||Olfactory Perception:1||Oligoastrocytoma:1||Oligodendroglioma:1||Oncogene:1||Optic canal decompression:1||Optic neuropathy:1||Optical coherence tomography:1||Orbital cavernous venous malformation:1||Orthotopic:1||Orthotopic animal model:1||Orthotopic xenograft model:1||Pglycoprotein:1||PARP inhibitor:1||PCV:1||PEGIFNalpha:1||PI3K/mTOR/AKT inhibitor:1||PIK3CAE542K:1||PLB1001:1||PSI domain:1||PTEN:1||PTTG1:1||Paclitaxel:1||Panobinostat:1||Patientderived xenografts:1||Patient‐derived glioblastoma stem‐like cells:1||Peptide:1||Perfusion MRI:1||Personalized medicine:1||Pharmacogenomic analysis:1||Pharmacogenomics:1||Phenotypes:1||Phosphorylated Chk1 (PChk1):1||Pituitary Neoplasms:1||Pituitary neuroendocrine tumor:1||Postoperative:1||Postoperative radiotherapy:1||Postural change:1||Preclinical trial:1||Primary central nervous system lymphoma:1||Primary culture:1||Primary treatment:1||Proactive Gamma Knife surgery:1||Programmed cell death 1 receptor:1||Prolactinoma:1||Propensity score matching:1||Protein Biochemistry:1||Pseudoprogression:1||Pterygopalatine fossa:1||Quality of life:1||Quantitative imaging:1||Quinazolineurea:1||RET fusion:1||RNF11:1||RNF20:1||RUNX1RUNX1T1:1||Rabbit:1||Radiati:1||Radiation:1||Radiation necrosis:1||Radiogenomic:1||Radiomic:1||Radiomics:1||Radioresistance:1||Radioresistant:1||Radiosensitivity:1||Receptor tyrosine kinase pathways:1||Receptormediated transcytosis:1||Reconstruction:1||Reconstructive outcome:1||Recurrent:1||Recursive partitioning analysis:1||Recursive partitioning analysis class:1||Relative cerebral blood volume:1||Renal cell carcinoma:1||Response assessment:1||Retinal nerve fiber layer:1||Retrochiasmatic:1||Retroinfundibular:1||Retrosigmoid:1||Retrosigmoid approach:1||Risk factors:1||Rod cells:1||SEMA3A:1||SREBP1c:1||STEMCELL:1||Salvage treatment:1||Schwannoma:1||Selenolate nucleophile:1||Selfrenewal pathways:1||Semaphorin3A:1||Semaphorin3A:1||Semiautomated cell panning:1||Semi‐ and pseudotypedretroviral replicating vector:1||Septal surgery:1||Shortcourse:1||Signal transducer and activator of transcription 3:1||Simpson grading system:1||Single cell analysis:1||Singlecell RNA sequencing:1||Sinonasal Outcome Test:1||Sinonasal pressure:1||Sinonasal tumor:1||Sinonasalrelated quality of life:1||Skull base defects:1||Skull base malignancy:1||Skull base neoplasms:1||Skull base reconstruction:1||Skull base tumor:1||Solitary fibrous tumor:1||Spinal cord injuries:1||Src kinase:1||Stem cell therapy:1||Stemness:1||Stroma:1||Subtype:1||Suicide gene:1||Superresolution:1||Surgery:1||Surgical approach:1||Surgical bed:1||Surgical technique:1||Survival outcomes:1||Systemic metastasis:1||T gene:1||TLX:1||TP53 mutations:1||TRAIL receptor:1||Talin1:1||Target therapy:1||Targeted sequencing:1||Telomerase:1||Temp:1||Themozolomide:1||Therapeutic effect:1||Therapeutic marker:1||Therapeutics:1||Threefraction gamma knife radiosurgery:1||Thyrotropinsecreting pituitary neuroendocrine tumor:1||Tile scan:1||Topography:1||Toxicity profile:1||Transsphenoidal approach:1||Transsphenoidal surgery:1||Translabyrinthine:1||Translocator protein 18 kDa (TSPO):1||Transorbital:1||Transorbital approach:1||Transsphenoidal surgeryp:1||Treatment resistance:1||Triple negative breast cancer:1||Tumor Volume:1||Tumor bed:1||Tumor laterality:1||Tumor progression locus 2:1||Tumor spheroids:1||Tumor suppressor gene:1||Tumor suppressor protein p53:1||Tumor treating fields:1||Tumor volume:1||Tumoral heterogeneity:1||Tumorigenesis:1||Twostaged gamma knife surgery:1||Upper clivus:1||VEGF:1||VEGF signaling:1||VEGFR2(KDR):1||Validation:1||Vandetanib:1||Vascular endothelial growth factor receptor:1||Ventriculoperitoneal shunt:1||Vestibular Schwannoma:1||Vortex keratopathy:1||19q codeletion:1||Whole exome sequencing:1||Wholebrain radiotherapy:1||Xenograft:1||absorbed dose:1||acellular dermal matrix:1||acute myeloid leukemia:1||adult human adipose stem cell:1||alphaSubunit:1||alternative splicing:1||amplification:1||angiogenesis inhibitor:1||antiVEGFR2 monoclonal antibody:1||antiangiogenic therapy:1||anticMet antibody:1||antiendothelial treatment:1||antimiR:1||antipsychotics:1||apoptosis:1||approach:1||artesunate:1||ascorbate peroxidase:1||atypical:1||bFGF:1||betacatenin:1||bevacizumab:1||bevacizumab resistance:1||bevacizumabresistance:1||biomarker:1||biomarkers:1||brain ischemia:1||brain location:1||brain metastases:1||brain perivascular tumor microenvironment:1||breast cancer brain metastasis:1||cMet inhibitor:1||cancer:1||cancer spheroids in Matrigel:1||cancer stem cells:1||cancer therapy:1||capmatinib:1||carboxyl esterase (CE):1||castration resistance:1||ccRCC:1||central nervous system lymphoma:1||cerebellar glioblastoma:1||cerebral metastatic lung cancer cells:1||characterization:1||chemotherapy:1||chro:1||cilengitide:1||clinical manifestation:1||clinical trial:1||clonogenic assay:1||combination:1||con:1||cranioorbital tumor:1||craniotomy:1||cross species reactivity:1||crossreactivity:1||cyclin D1:1||cyclin E:1||cytologenic anaplasia:1||data science:1||delivery efficiency:1||deubiquitination:1||diagnosis:1||diffusion tensor imaging:1||disease recurrence:1||doxorubicin:1||drug repurposing:1||drug resistant:1||drug response:1||drug screening:1||dynamic magnetic resonance imaging:1||electron microscopy:1||endoscope:1||endoscopic:1||endoscopic endonasal surgery:1||endoscopic surgery:1||epidermal growth facor receptor:1||epidermal growth factor receptor:1||ethnic:1||evolution:1||experimental animal:1||extracellular vesicles:1||extracranial disease control:1||extracranial metastasis:1||fascia lata:1||frail patients:1||fully human neutralizing antibody:1||gammadelta T cells:1||gammadelta Tcell receptor repertoire:1||gene expression profile:1||gene expression signatures:1||gene fusion:1||genetics:1||genomic characterization:1||genomic profile:1||genomic profiling:1||genomics:1||germ cell tumor:1||glioblastoma stem cell:1||glioblastoma stem cells:1||glioblastoma subclassification:1||glioma stem cell:1||glioma stem cells:1||glioma stemlike cells:1||gliomas:1||granular cell astrocytoma:1||granular cell tumor:1||grosstotal resection:1||growth factor:1||headache:1||hemangiopericytoma:1||hepatocellular carcinoma cell line:1||hepatocyte g:1||hepatocyte growth factor:1||highcontent analysis:1||highthroughput drug screening:1||hippocampus:1||histogenesis:1||hydrocephalus:1||hydroxyapatite:1||hypermutation:1||immune cells:1||immune repertoire sequencing:1||immune response:1||immunohistochemistry:1||in vitro expansion:1||in vitro extracellular matrix remodeling:1||intracranial:1||intracranial hypotension:1||intracranial schwannoma:1||intratumoral injection:1||intraventricular injection:1||leptomeningeal dissemination:1||leptomeningeal enhancement:1||longitudinal glioblastoma:1||lymphopenia:1||lysyltRNA synthetase:1||macrophages/microglia:1||malignant glioma:1||mediobasal temporal region:1||mesenchymal:1||mesenchymal differentiation:1||metastatic brain tumor:1||metronomic:1||microfluidic coculture chip:1||mismatch repair deficiency:1||mitochondria calcium uniporter:1||monitoring:1||monoclonal:1||monoclonal antibody:1||mouse model:1||multitRNA synthetase complex:1||multilayer technique:1||multisession r:1||multisession radiosurgery:1||muscle invasive bladder cancer:1||mutations:1||nasoseptal flap:1||neoantigenicity:1||neural stem cells:1||neural stemlike cells:1||neuronal:1||newly diagnosed glioblastoma:1||nonsmall cell lung:1||nonsmall cell lung cancer:1||nonsmallcell lung:1||noninvasive method:1||notch signaling:1||oligodendroglioma:1||oncogenes:1||oncosis:1||optic nerve:1||optic radiation:1||orbital tumor:1||orbital tumors:1||paclitaxel:1||parametric modeling:1||pathological grade:1||pathological subtype:1||patient derived xenograft models:1||patientderived tumor cell:1||patientderived xenograft:1||personalized medicine:1||petrous apex:1||pharmacodynamics:1||phase 1:1||phase I:1||piecewise exponential distribution:1||pituitary diseases:1||pituitary neoplasms:1||pituitary surgery:1||precision neurooncology:1||primary CNS lymphoma:1||progno:1||proneural to mesenchymal transition:1||proneuraltomesenchymal transition:1||prostate cancer:1||proteogenomics:1||pseudopalisading cell:1||quality assurance:1||rabbit:1||radiation therapy:1||radiogenomic analysis:1||radioresist:1||radioresistance:1||randomized phase II study:1||recurrenceinitiating cell:1||recurrent:1||refractory cancer:1||renal cell carcinoma:1||risk factor:1||risk score:1||rituximab:1||rod cells:1||salvage therapy:1||saracatinib (AZD0530):1||secondary glioblastomas:1||secondary neuralgia:1||selfrenewal capacity:1||senescence:1||sequencing:1||serologic biomarker:1||shortterm cultivation screening platform:1||sinonasalrelated quality of life:1||skull base:1||skull base chordoma:1||skull base reconstruction:1||skull base surgery:1||solid tumors:1||solitary fibrous tumor:1||spatial identity:1||sphere formation:1||spliceosome:1||splicing var:1||stemness:1||stereotactic device:1||subtypes:1||synapse:1||targeted therapeutics:1||targeted therapy:1||telomerase reverse transcriptase:1||telomerase reverse transcriptase promoter mutation:1||temporal horn:1||teratoma:1||thalidomide:1||therapeutic resistance:1||therapy:1||tissue distribution:1||tissue factor:1||toxicity:1||transcranial:1||transcription factor:1||transcriptomic characterization:1||translatome:1||transorbital surgery:1||transsphenoidal approach:1||trastuzumab:1||trigeminal neuralgia:1||tuberculum sellae:1||tumor evolution:1||tumor growth inhibition:1||tumor heterogeneity:1||tumor immune microenvironment:1||tumor progression:1||tumor progression locus 2:1||tumor purity:1||tumorassociated macrophages:1||tumorigenesis:1||twodrug combination:1||unmethylated MGMT promoter:1||use infiltrating glioma:1||vandetanib:1||vascular endothelial growth factor receptor:1||visual complication:1||visual outcome:1||well plate:1||WHO grade:1||1p:1||1p/19q:1||1p/19q codeletion:1||1p19q:1||2SGKR:1||3D co culture:1||6 inhibitor:1||96pillar:1||ABC transporters:1||ACNUCDDP:1||ADC:1||AIMP2:1||ALK:1||APAF1:1||ATM:1||Acromegaly:1||Acute obstructive hydrocephalus:1||Adhesion molecule:1||Adjuvant:1||Adjuvant chemotherapy:1||Adjuvant treatment:1||Adoptive immunotherapy:1||Adult:1||Adult neural stem cell:1||Adult stem cells:1||Akt:1||Amyotrophic lateral sclerosis:1||Anaplastic gliomas:1||Angiogenesis:1||Angiomatous meningioma:1||Antitumor activity:1||Arraycomparative genomic hybridization:1||Aryl selenide:1||Asymptomatic brain metastases in NSCLC:1||Atypical meningioma:1||Autologous cytokineinduced killer cell:1||BBBPenetrating therapeutics:1||BRAF:1||Bevacizumab:1||Biological Sciences:1||Biomarkers:1||Blood brain barrier (BBB):1||Boost:1||Bortezomib:1||Brain edema:1||Brain tumor cell:1||Breast cancer:1||Bystander effect:1||CD109:1||CD151:1||CD90:1||CDK4:1||CNS metastasis:1||CNS tumours:1||CPT11:1||Cancer Systems Biology:1||Cancer associated fibroblast:1||Cancer of the uterine cervix:1||Cancer panel:1||Cancer stem cells:1||Carcinoma:1||Carcinoma, Nonsmallcell lung:1||Cavernous sinus invasion:1||Cell culture:1||Cellbased Assays:1||Cellbased panning:1||Central hyperthyroidism:1||Central nervous system:1||Central neurocytoma:1||Cerebellar injury:1||Cerebellopontine angle tumor:1||Cerebrospinal fluid:1||Cerebrospinal fluid leakage:1||Chemokine1:1||Chemoradiotherapy:1||Chondrosarcoma:1||Chordoma:1||Claspin:1||Classification:1||Clinical outcome:1||Clinical study:1||Clinical trial:1||Clivus:1||Clonogenic assay:1||Combined approach:1||Combined endoscopic surgery:1||Communicating hydrocephalus:1||Complication:1||Concomitant chemoradiation:1||Contrast agents:1||Conventional Treatment:1||Convolutional neural network:1||Corneal epithelial change:1||Cot:1||Cranial nerve:1||Crizotinib:1||Crossreactivity:1||Cytokineinduced killer cells:1||Cytologenic anaplasia:1||DNA damage:1||DNA damage checkpoint:1||DNA methylation:1||Delayed:1||Diagnosis:1||Diffusionweighted imaging:1||Disease progression:1||Diselenide reduction:1||Dithiothreitol:1||Docking:1||Dopamine receptor:1||Dorsum sellar resection:1||Doseescalation study:1||Dual suicide gene therapy:1||Dynamic contrastenhanced MRI:1||Dynamic susceptibility contrast MRI:1||EGFR inhibitor:1||EGFRtargeting therapeutic antibody:1||EOT:1||Endonasal:1||Endonasal transpterygoid:1||Endoportguided endoscopy:1||Endoscope:1||Endoscopic optic nerve decompression:1||Endoscopic repair:1||Endoscopic transorbital approach:1||Ependymoma:1||Epidermal growth facor receptor:1||Epithelialmesenchymal transition:1||Extended endoscopic endonasal skull base surgery:1||Extracranial metastasis:1||FGFR inhibitor:1||FGFR3specific antibody:1||Facial Nerve:1||Facial nerve preservation surgery:1||

STATISTICS: Total View:; Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE